A phase I and pharmacokinetic study of the combination of capecitabine anddocetaxel in patients with advanced solid tumours

Capecitabine and docetaxel are both active against a variety of solid tumou rs, while their toxicity profiles only partly overlap. This phase I study w as performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds. Thirty-three patients were treated w ith capecitabine administered orally twice daily on days 1-14. and docetaxe l given as a 1 h intravenous infusion on day 1. Treatment was repeated ever y 3 weeks. The dose of capecitabine ranged from 825 to 1250 mg m(-2) twice a day and of docetaxel from 75 to 100 mg m(-2). The dose-limiting toxicity (DLT) was asthenia grade 2-3 at a dose of 1000 mg m(-2) bid of capecitabine combined with docetaxel 100 mg m-2. Neutropenia grade 3-4 was common (68% of courses), but complicated by fever in only 2.4% of courses. Other non-ha ematological toxicities were mild to moderate. There was no pharmacokinetic interaction between the two drugs. Tumour responses included two complete responses and three partial responses. Capecitabine 825 mg m(-2) twice a da y plus docetaxel 100 mg m(-2) was tolerable, as was capecitabine 1250 mg m( -2) twice a day pills docetaxel 75 mg m(-2). (C) 2000 Cancer Research Campa ign.